GPGraziela M. A. Pereira

Graziela M. A. Pereira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Graziela M. A. Pereira has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Flávia Chaves Uchôa

    Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Department of Pharmaceutical Sciences, Campus Universitário I, Federal University of Paraiba, Castelo Branco III-Cidade Universitária, João Pessoa 58051-900, PB, Brazil

    1 shared publication
  • Anne B. C. Barros

    Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Department of Pharmacy, Federal University of Paraíba (UFPB), Campus I-Castelo Branco III., Joao Pessoa 58051-900, PB, Brazil

    1 shared publication
  • Francisco Humberto Xavier Junior

    Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Department of Pharmaceutical Sciences, Campus Universitário I, Federal University of Paraiba, Castelo Branco III-Cidade Universitária, João Pessoa 58051-900, PB, Brazil

    1 shared publication
  • José Maria Barbosa-Filho

    Pharmaceutical Technology Laboratory, Department of Pharmaceutical Sciences, Federal University of Paraíba, João Pessoa 58051-900, Paraíba, Brazil

    1 shared publication
  • Karla Patrícia de Oliveira Luna

    State University of Paraíba, Center for Biological and Health Sciences, Avenue Baraúnas, 351, Universitário, Campina Grande, 58429-500, Brazil

    1 shared publication
  • Karla Samara Rocha Soares

    Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Department of Pharmacy, Federal University of Paraíba (UFPB), Campus I-Castelo Branco III., Joao Pessoa 58051-900, PB, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Emerging Trends in Snake Venom-Loaded Nanobiosystems for Advanced Medical Applications: A Comprehensive Overview

    by Álisson E. F. Alves, Anne B. C. Barros, Lindomara C. F. Silva, Lucas M. M. Carvalho, Graziela M. A. Pereira, Ana F. C. Uchôa, José M. Barbosa-Filho, Marcelo S. Silva, Karla P. O. Luna, Karla S. R. Soares, et al.

    Advances in medical nanobiotechnology have notably enhanced the application of snake venom toxins, facilitating the development of new therapies with animal-derived toxins. The vast diversity of snake species and their venom complexities underline the need for ongoing research. This review is dedicated to exploring the integration of snake venom with nanoparticles to enable their use in human therapies aiming to develop treatments. The complex mixture of snake venom not only inflicts significant pathological effects but also offers valuable insights for the creation of innovative therapies, particularly in the realm of nanobiotechnology. Nanoscale encapsulation not only mitigates the inherent toxicity of snake venom but also amplifies their antitumoral, antimicrobial, and immunomodulatory properties. The synergy between venom-derived macromolecules and nanotechnology offers a novel pathway for augmenting the efficacy and safety of conventional antivenom therapies, extending their applicability beyond treating bites to potentially addressing a myriad of health issues. In conclusion, nanotechnology presents a compelling therapeutic frontier that promises to improve current treatment modalities and ameliorate the adverse effects associated with venomous snakebites.